BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. by Derré, L. et al.
Research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 1      January 2010  157
BTLA mediates inhibition of human  
tumor-specific CD8+ T cells that can  
be partially reversed by vaccination
Laurent Derré,1 Jean-Paul Rivals,2 Camilla Jandus,1 Sonia Pastor,3 Donata Rimoldi,1  
Pedro Romero,1 Olivier Michielin,1,4 Daniel Olive,3 and Daniel E. Speiser1
1Ludwig Institute for Cancer Research, Lausanne, Switzerland. 2University Hospital Center and University of Lausanne (CHUV),  
Lausanne, Switzerland. 3INSERM UMR 891, Institut Paoli Calmettes, Marseille, France.  










































































Related Commentary, page 76  
Downloaded from http://www.jci.org on May  5, 2015.   http://dx.doi.org/10.1172/JCI40070
research article
158	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 1      January 2010
Figure 1
BTLA (CD272) is downregulated with progressive CD8+ T cell differentiation, except in tumor antigen–specific CD8+ T cells. Direct ex vivo 
analysis of CD8+ T cells from PBMCs by flow cytometry. (A) Representative examples of BTLA expression by Melan-AMART-1– and virus-specific 
(EBV, CMV, and influenza virus [FLU]) CD8+ T cells from healthy donors (HD) and melanoma patients. BTLA+ T cells were distinguished from 
BTLA– T cells using a threshold established according to the autologous naive T cell subset, which is always BTLA positive. Numbers indicate 
percentage of positive or negative cells. (B) Comparison of BTLA expression on total CD8+ and virus- and Melan-A–specific T cells, from healthy 
individuals and unvaccinated melanoma patients. **P < 10–2 for each of the 2 populations of Melan-A–specific T cells compared with all 5 other 
populations. (C–E) BTLA expression in subsets of CD8+ T cells of healthy individuals (n = 58), upon definition of early and late differentiation 
stages by CD45RA and CCR7 expression (i.e. naive [N, CD45RA+CCR7+], central memory [CM, CD45RA–CCR7+], effector memory [EM, 
CD45RA–CCR7–], and effector memory RA+ [EMRA, CD45RA+CCR7–] cells), gated as shown in C; a representative example demonstrates 
the narrow positive peak observed in phenotypic naive cells. (D) Statistical assessment of BTLA+ CD8+ T cell subsets. (E) GMFI data, showing 
results compatible with those presented in D. Overall GMFI was determined by including the whole range from BTLA-negative to -positive cells, 
as shown in C. GMFI data were normalized to values determined in autologous naive CD8+ T cells.
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Regulation of proliferation and cytokine production of primary CD8+ 









Persistence of BTLA expression on Melan-AMART-1–specific lymphocytes despite effector cell differentiation. (A) Analysis of BTLA expression 
by Melan-AMART-1–specific T cells depending on differentiation. Representative example of PBMCs from an unvaccinated melanoma patient. 
(B) Percentages of BTLA+ CD8+ T cells from healthy individuals (gray, n = 58) and unvaccinated melanoma patients (white, n = 18); and from 
Melan-AMART-1 tetramer+ CD8+ T cells from unvaccinated patients (black, n = 14). Data from healthy donors (same as in Figure 1D) are shown 
again for comparison. Circulating central memory Melan-AMART-1–specific cells were rare, precluding analysis for BTLA expression. (C and D) 
BTLA expression by CD45RA+/– and CCR7+/– T cells from normal lymph nodes (NLN, n = 18) and tumor-infiltrated lymph nodes (TILN, n = 6) from 
melanoma patients. (C) Representative example and (D) comparison of BTLA expression in CD8+ T cells and Melan-AMART-1–specific T cells. In 
NLNs, Melan-AMART-1–specific T cells are all naive. Light gray, whole CD8+ T cells in NLNs (n = 18); white, Melan-AMART-1 tetramer+ CD8+ T cells 
in NLNs (n = 18); black, whole CD8+ T cells in TILNs (n = 6); dark gray, Melan-AMART-1 tetramer+ CD8+ T cells in TILNs (n = 6).
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Expression of HVEM and its ligands BTLA and LIGHT by melanoma cells; and BTLA-mediated functional inhibition of tumor antigen–specific 
BTLA+ CD8+ T cells. (A) Representative examples of BTLA, LIGHT, and HVEM expression by the melanoma cell lines Me 280, Me 261, and 
Me 290. Cells were stained with isotype control (open histograms) or with anti-HVEM, anti-BTLA, or anti-LIGHT mAb (filled histograms) (B) 
Relative expression of HVEM, BTLA, and LIGHT by melanoma cell lines, expressed as ratio fluorescence intensity (RFI), i.e., MFI with specific 
mAb/MFI with isotype control. Of 40 melanoma cell lines analyzed, 19 were highly positive (white dots), 7 weakly positive (gray dots), and 14 
negative for HVEM expression (black dots). None of the melanoma cell lines expressed BTLA or LIGHT (black dots). (C) HVEM expression (in 
reddish brown) detected in paraffin-embedded tumor sections from 16 tumors of 14 melanoma patients. Examples show tumor tissues that were 
HVEM-negative, weakly positive (<10% HVEM+ tumor cells) or strongly positive (>50% positive tumor cells). Original magnification, ×200. (D) 
Melan-AMART-1/HLA-A*0201–specific CD8+ T cell clones (cl.) 618-45, 618-4, and 618-420 were stimulated by melanoma cell lines Me 275 and 
Me 290 (both Melan-A+, HLA-A*0201+, HVEM+). The graph shows fold increase in IFN-γ production by Melan-AMART-1–specific clones in the pres-
ence of blocking antibody BTLA-8.2, relative to isotype control antibody. IFN-γ production was determined by ELISA in supernatants of 24-hour 
cultures. BTLA expression by T cell clones was assessed by flow cytometry with BTLA-specific antibody (filled histograms) and isotype control 
(open histograms). GMFI is indicated in parentheses.
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these data reveal an inhibitory role for BTLA in CD8+ T cell pro-
liferation and cytokine production but not cytotoxicity.












































HVEM expression analyzed by immunohistochemistry
HVEM expression Negative < 10% 10%–50% > 50%
Number of tumors (n = 16) 1 3 4 8
Percentage of tumors 6.25 18.75 25 50
The table summarizes all results from immunohistochemical HVEM 
staining of paraffin-embedded tumor sections of 16 tumors from 14 
patients with melanoma.
Figure 4
Repeated vaccination with Melan-AMART-1 peptide, IFA (Montanide ISA-51), and CpG (PF-3512676) induces downregulation of BTLA on Melan-A– 
specific CD8+ T cells. (A) Representative examples of A2/Melan-AMART-1 tetramer and BTLA staining in unvaccinated and vaccinated patients. 
Numbers indicate percentages of positive or negative cells. w/o, without. (B) Comparison of BTLA expression in Melan-AMART-1–specific CD8+ 
T cells from 14 unvaccinated patients, 24 patients vaccinated with peptide but without CpG, and 16 patients vaccinated with peptide plus CpG. 
(C) Expression of BTLA by Melan-AMART-1–specific CD8+ T cells (black) and whole CD8+ T cells (white) according to CD8 differentiation stages 
after vaccinations without CpG (upper panel; n = 24) or with CpG (lower panel; n = 16).
Downloaded from http://www.jci.org on May  5, 2015.   http://dx.doi.org/10.1172/JCI40070
research article

























































tion upon repeated vaccination 
with CpG. (A) Representative 
dot plots of A2/Melan-AMART-1 tet-
ramer and BTLA staining (gated 
on CD8+ T cells) of PBMCs 
from 2 patients, before vaccina-
tion and after 16 vaccinations, 
respectively. Numbers indicate 
percentages of positive or nega-
tive cells. (B and C) Correlations 
between numbers of vaccinations 
without or with CpG and percent-
ages of BTLA+ T cells among 
(B) Melan-A–specific CD8+ T 
cells and whole CD8+ T cells 
and (C) subsets of Melan-A– 
specific CD8+ T cells.
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Functional inhibition of CD8+ T cells depending on BTLA expression and HVEM triggering. (A) Direct ex vivo analysis of percentage of 
A2/Melan-AMART-1 tetramer+ CD8+ T cells among PBMCs, in relation to their BTLA expression, after vaccination without and with CpG. (B) In 
vitro expansion of Melan-AMART-1 tetramer+ T cells from healthy donors, after 10 days of stimulation with peptide-loaded DCs, in the absence 
versus presence of blocking mAb BTLA-8.2. (C and D) IFN-γ (C) and TNF-α (D) production by BTLA+ antigen-specific CD8+ T cells after 
4 hours of peptide stimulation of PBMCs assessed ex vivo, i.e., without prior in vitro cultivation. Representative histograms of PBMCs from 
patient LAU 618 (after 2 vaccinations, with CpG) and from healthy donor BCB122 stimulated by SKMEL37 cells expressing HVEM or not, 
loaded with Melan-AMART-1 or EBV peptides, respectively. Histograms are gated on tetramer+ T cells. Percentages of cytokine-positive cells 
are indicated. (E) Significant correlation between percentages of BTLA+ tetramer+ T cells and percentages of IFN-γ production inhibition (i.e., 
reduction when stimulated with HVEM+ SKMEL37 cells as compared with HVEM– SKMEL37 cells). Each dot represents a single experiment 
with Melan-AMART-1– or EBV-specific T cells.
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Downregulation of BTLA by primary CD8+ T cells upon T cell receptor activation and HVEM ligation. (A) Representative example of BTLA down-
regulation by BTLA+ EBV-specific CD8+ T cells from PBMCs of healthy donor BCB136 upon EBV peptide stimulation with target cells expressing 
HVEM or not. Histograms are gated on CD8+ EBV+ T cells. Percentages of BTLA+ cells (and GMFI in parentheses) are indicated. (B) Percent-
ages of BTLA expression by antigen-specific CD8+ T cells after stimulation with SKMEL37 cells expressing HVEM or not. Each dot represents 
a single experiment with Melan-AMART-1– or EBV-specific T cells. (C and D) Kinetic analysis of surface BTLA expression (C) and expansion (D) 
of EBV-specific CD8+ T cells upon stimulation with irradiated target cells expressing HVEM or not, in the presence or absence of EBV peptide. 
Results for 2 of 5 representative healthy donors tested are shown.
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Characterization of new BTLA-specific antibodies (BTLA-7.1 and -8.2) and 
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